Eli Lilly announced impressive Q1 2024 financial results, with revenue surging by 26% YoY and exceeding expectations for earnings per share. The company raised its full-year 2024 revenue guidance ...
Glencar has taken over the construction of a life sciences building near Cambridge from collapsed contractor Readie. Readie ...
The Price to Earnings ratio of 120.04 for this company is 1.74x above the industry average, indicating a premium valuation associated with the stock. It could be trading at a premium in relation ...
Shares of Eli Lilly (NYSE:LLY) reached new all-time highs this week, driven by the continued share price and fundamental momentum, and by what some would say is the obesity market hype. The former ...
Tirzepatide sales are off the charts but could be much higher if not for supply constraints. Eli Lilly will invest $9 billion in a manufacturing facility to keep up with demand for its weight ...
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said. New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast. The FDA approved the pharma ...
The incident comes after a series of official investigations last year related to the issuance of fake birth certificates at a time when China is trying to boost its birth rate. Cardinal now expects ...
QurAlis granted Lilly an exclusive, worldwide license to develop and commercialize QRL-204. The agreement includes a research and development collaboration to identify and develop additional ...